SCHEMBL16374026

SCHEMBL16374026

NC[C@]1(CO)O[C@@H](n2cnc3c(N)ncnc32)[C@H](F)[C@@H]1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 3/20 0.54
▸ POLB P06746 1/20 0.54
▸ PI4KA P42356 2/20 0.53
▸ PI4K2B Q8TCG2 2/20 0.53
▸ PI4K2A Q9BTU6 2/20 0.53
▸ PI4KB Q9UBF8 2/20 0.53
▸ DPP4 P27487 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ SLC28A1 O00337 1/20 0.53
▸ MAP3K7 O43318 1/20 0.53
▸ SLC28A2 O43868 1/20 0.53
▸ GAPDH P04406 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ ADORA2A P29274 1/20 0.53
▸ ADORA2B P29275 1/20 0.53
▸ ADORA1 P30542 1/20 0.53
▸ STAT6 P42226 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ DOT1L Q8TEK3 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16373916 1.00 ADORA3 (0.54) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL20629107 0.91 ADORA3 (0.52) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL15070711 0.91 ADORA3 (0.53) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL31652878 0.90 ADORA3 (0.52) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL15070701 0.90 AHCY (0.54) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL15070706 0.90 ADORA3 (0.52) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL16373932 0.85 AHCY (0.56) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL16374027 0.85 AHCY (0.56) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL26311766 0.84 ADORA3 (0.55) ADORA3POLBPI4KAPI4K2BPI4K2A
SCHEMBL16375327 0.83 AHCY (0.46) ADORA3POLBPI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210106604-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2021-04-15 — — US disclosed
US-10780105-B2 Substituted nucleosides, nucleotides and analogs thereof Janssen Biopharma, Inc. (US) 2020-09-22 — — US disclosed
EP-3424938-B1 4'-AZIDOALKYL-SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN BIOPHARMA INC (US) 2020-07-22 — — EP disclosed
US-10696708-B2 Substituted nucleosides, nucleotides and analogs thereof Janssen Biopharma, Inc. (US) 2020-06-30 — — US disclosed
US-20190054108-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2019-02-21 — — US disclosed
EP-3424938-A1 4'-AZIDOALKYL-SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Alios Biopharma, Inc. (US) 2019-01-09 — — EP disclosed
US-20180194793-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2018-07-12 — — US disclosed
EP-3013843-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA INC (US) 2018-05-30 — — EP disclosed
US-9932363-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2018-04-03 — — US disclosed
US-20170143751-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2017-05-25 — — US disclosed
US-9603863-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2017-03-28 — — US disclosed
US-9603863-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2017-03-28 — — US disclosed
US-20160318967-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2016-11-03 — — US disclosed
US-9422322-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2016-08-23 — — US disclosed
WO-2015200205-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2015-12-30 — — WO disclosed
US-20150366887-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-12-24 — — US disclosed
US-20150366887-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-12-24 — — US disclosed
US-20150005251-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICA NV 2015-01-01 — — US disclosed
US-20150005251-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICA NV 2015-01-01 — — US disclosed
WO-2014209983-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190054108-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B ADORA3 79/4885POLB 224/4885PI4KA 1127/4885
US-10696708-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NT5C3B, NT5C2 ADORA3 63/4885POLB 414/4885PI4KA 1514/4885
US-20170143751-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B ADORA3 79/4885POLB 224/4885PI4KA 1127/4885
US-20150366887-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B ADORA3 79/4885POLB 224/4885PI4KA 1127/4885
US-20180194793-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NT5C3B, NT5C2 ADORA3 63/4885POLB 414/4885PI4KA 1514/4885
US-10780105-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NUDT1, NT5C3B ADORA3 79/4885POLB 224/4885PI4KA 1127/4885
US-20160318967-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NT5C3B, NT5C2 ADORA3 63/4885POLB 414/4885PI4KA 1514/4885
US-20150005251-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NT5C3B, NT5C2 ADORA3 63/4885POLB 414/4885PI4KA 1514/4885
US-20210106604-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B ADORA3 79/4885POLB 224/4885PI4KA 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback